Matthew J. Akiyama

Submitted by Anonymous (not verified) on
Full Name
Matthew J. Akiyama
Profile Image URL
https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/a703c590-85e5-11ec-a5a4-39080ebc53e5.jpg
Type
Provider
Faculty
First Name
Matthew
Last Name
Akiyama
NPI
1316259419
Faculty ID
14789
Clinical Terms
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-medicine
Gender
Male
Provider Type
Primary Care
Email
matthew.akiyama@einsteinmed.edu
Phone
718-920-7175
Titles
Type
Academic
Department
Department of Medicine
Department Link
Rank
Associate Professor
Division
General Internal Medicine
Type
Administrative
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84544 40.84518)
Address Line 1
1621 Eastchester Road
City
Bronx
State
NY
Zip
10461-2301
Location Title
Montefiore Medical Group-Comprehensive Family Care Center (CFCC)
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8815777 40.8798456)
Address Line 1
Montefiore Medical Center
Address Line 3
3330 Kossuth Avenue
City
Bronx
State
NY
Zip
10467
Location Title
Montefiore Medical Center
Education and Trainings
Education Type Label
Medical Education
Education Institution
St. Georges University School of Medicine
Education Type Label
Fellowship
Education Institution
New York University Medical Center
Education Type Label
Residency
Education Institution
University of Hawaii School of Medicine
Professional Interests

<p>Dr. Akiyama is an Associate Professor of Medicine and Clinician-Investigator in the Divisions of General Internal Medicine and Infectious Diseases. In addition to providing care and treatment to people living with HIV, hepatitis C virus (HCV), and substance use disorders, Dr. Akiyama conducts research focusing on HCV among socioeconomically marginalized populations with particular emphasis on the intersection of HCV in the criminal legal system and sub-Saharan Africa. Dr. Akiyama is the recipient of a K99/R00 award from the National Institute on Drug Abuse to develop and test an innovative strategy to improve linkage to and retention in HCV treatment among individuals recently released from jail. He is also the recipient of an Avenir Award from the National Institute on Drug Abuse focused on HCV Transmission Networks Among People Who Inject Drugs.&nbsp;</p>
<p>Dr. Akiyama&nbsp;completed his Infectious Diseases Fellowship at New York University/Bellevue Hospital Center and a Master of Science in Medical Anthropology at University College London in London, England.&nbsp;</p>
<p><strong>Selected Awards</strong>&nbsp;<strong>&amp; Honors</strong></p>
<p>Recipient, Justice Community Opioid Innovation Network LEAP Investigator Scholarship (2020)</p>
<p>Member, New York State Governor's Hepatitis C Elimination Task Force (2018)</p>
<p>Albert Einstein College of Medicine KL2 Career Development Award (2017)</p>

Research Areas
I study how people access and utilize hepatitis C and HIV treatment and prevention services with particular emphasis on their intersection with substance use and the criminal legal system in the U.S. and sub-Saharan Africa.
CHAM Provider
Off
Professional Title
M.D.
M.S.
Clinical Focus

Provide care and treatment to people living with and at risk for HIV, viral hepatitis, and substance use disorders.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Conduct research focusing on HIV and viral hepatitis.<quillbot-extension-portal></quillbot-extension-portal>

Selected Publications

<div class="cit">
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;"><strong>Akiyama MJ</strong>, Spaulding AC, Nijhawan AE.&nbsp;Long-Acting Injectable Antiretrovirals in Incarcerated Populations - Challenges and Opportunities.&nbsp;</span></span><span style="font-family: Calibri, sans-serif; font-size: 16px;">N Engl J Med. 2</span><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">022 Nov 10;387(19):1728-1730.</span></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Kronfli N, Cabezas J, Sheehan Y, Thurairajah PH, Lines R, Lloyd AR; International Network on Health and Hepatitis in Substance Users&ndash;Prisons Network.&nbsp;Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.&nbsp;Lancet Gastroenterol Hepatol. 2021 May;6(5):391-400.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong><span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">, Muller A, Huang O, Lizcano J, Nyakowa M, Riback L, Ross J, Bundi H, Kulabi ES, Mwangi AM, Musyoki H, Cherutich P, Kurth A.</span> Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study. <span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Glob Public Health. 2021 Mar 9:1-13.</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Spaulding AC, Rich JD. Flattening the Curve for Incarcerated Populations - Covid-19 in Jails and Prisons. N Engl J Med.&nbsp;2020 May 28;382(22):2075-2077.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Lipsey D,<sup>&nbsp;</sup>Ganova-Raeva L, Punkova L, Agyemang L, Sue A, Ramachandran S, Khudyakov Y, Litwin AH. A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.&nbsp;J Infect Dis. 2020 Mar 9.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Cleland CM, Lizcano J, Cherutich P, Kurth A. Hepatitis C Prevalence, Estimated Incidence, Risk Behaviors, and Genotypic Distribution Among People Who Inject Drugs Accessing Harm Reduction Services in Kenya: A Retrospective Cohort Study. Lancet ID.&nbsp;2019 Nov;19(11):1255-1263.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Columbus D, MacDonald R, Jordan AO, Schwartz J, Litwin AH, Eckhardt B, Carmody E.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/31395019"><span style="color: black;">Linkage to hepatitis C care after incarceration in jail: a prospective, single arm clinical trial.</span></a>&nbsp;BMC Infect Dis. 2019 Aug 8;19(1):703.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH.&nbsp;Intensive&nbsp;Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy.&nbsp;Annals of Internal Medicine.&nbsp;2019 Apr 9.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Spaulding AC, Graham CS,&nbsp;<strong>Akiyama MJ</strong>, Chhatwal J, Nijhawan AE, Ninburg MH, Rich JD, Strick LB, Taylor LE, Trooskin SB, Westergaard RP, Sabol WJ. HCV prevalence estimates among incarcerated persons.&nbsp;Hepatology. 2019 Apr 2.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Norton BL,&nbsp;<strong>Akiyama MJ</strong>, Zamor PJ, Litwin AH.&nbsp;Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice. Infect Dis Clin North Am. 2018 Jun;32(2):347-370.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Feffer R, Von Oehsen III WF, Litwin AH. Drug Purchasing Strategies to Treat People With Hepatitis C in the Criminal Justice System<strong>.&nbsp;</strong>AJPH. 2018 May;108(5):607-608.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Agyemang L, Arnsten, JH, Heo M, Norton BL, Schackman BR, Linas BP, Litwin AH.&nbsp;Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy.&nbsp;BMC Infect Dis. 2018 Feb 9;18(1):74.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">MacDonald R,&nbsp;<strong>Akiyama MJ</strong>, Kopolow A, Rosner Z, McGahee W, Joseph R, Jaffer M, Venters H. Full Title: Feasibility of Treating Hepatitis C in a Transient Jail Population. Open Forum Infect Dis.&nbsp;2017 Jul 7;4(3):ofx142.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Kaba F, Rosner Z, Alper H, Kopolow A, Litwin A, Venters H, Macdonald R. Correlates of Hepatitis C Virus Infection in the Targeted Testing Program of the New York City Jail System: Epidemiologic Patterns and Priorities for Action. Public Health Reports.&nbsp;2017 Jan/Feb;132(1):41-47.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Kaba F, Rosner Z, Alper H, Holzman RS, MacDonald R. Hepatitis C Screening of the &ldquo;Birth Cohort&rdquo; (b. 1945-1965) and younger inmates of New York City Jails.&nbsp;AJPH.&nbsp;2016 Jul;106(7):1276-7.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Feller DJ,&nbsp;<strong>Akiyama MJ</strong>, Gordon P, Agins BD. Readmissions in HIV-infected Inpatients: A Large Cohort Analysis.&nbsp;JAIDS.&nbsp;2016 Apr 1;71(4):407-12.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">BardfieldJ, Agins B,&nbsp;<strong>Akiyama MJ</strong>, Mutandi G, Basenero A, Luphala P, Kaindjee-tjituka F, Natanael S, Hamunime N. A Quality Improvement Approach to Capacity Building in Low- and Middle-Income Countries: The case of HEALTHQUAL International. AIDS.&nbsp;2015 Jul;29 Suppl2:S179-86. &nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Vo PK, Vutien P,&nbsp;<strong>Akiyama MJ</strong>, Vu VD, Ha NB, Piotrowski JI, Wantuck J, Roytman MM, Tsai N, Cheung R, Li J, Nguyen MH. Poor Sustained Virologic Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Digestive Diseases and Sciences 2015 Apr;60(4):1045-51.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Piotrowski JI, Roytman MM, Chan A, Hong LK, Huddleston L, Trujillo R, Tsai N. New Triple Therapy for Chronic Hepatitis C: Real Life Clinical Experience in a Community Setting. Hawaii Journal of&nbsp;Medicine and Public Health 2013 Sep;72(9 Suppl 4):6-13.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
</div>

EMR ID
78529
Is Open Scheduling
On
Subscribe to Late Syphilis